Kymera Therapeutics (KYMR) Stock Forecast & Price Target

$49.90

+3.46 (+7.45%)

(As of 12:45 PM ET)

Kymera Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Based on 13 Wall Street analysts who have issued ratings for Kymera Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 4 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for KYMR.

Consensus Price Target

$48.67
-2.47% Downside

High Forecast	$65.00
Average Forecast	$48.67
Low Forecast	$30.00

According to the 13 analysts' twelve-month price targets for Kymera Therapeutics, the average price target is $48.67. The highest price target for KYMR is $65.00, while the lowest price target for KYMR is $30.00. The average price target represents a forecasted downside of -2.47% from the current price of $49.90.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	4 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$48.67	$45.90	$42.70	$48.10
Forecasted Upside	-2.47% Downside	18.20% Upside	29.83% Upside	95.93% Upside

This Crypto Is Set to Explode in September (Ad)

With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024.

Go here to get full details on this crypto now.

KYMR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KYMR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Kymera Therapeutics Stock vs. The Competition

Type	Kymera Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.77	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-0.52% Downside	977.99% Upside	6.72% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/9/2024	Leerink Partnrs 0 of 5 stars	F. Khurshid Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/9/2024	Leerink Partners 1 of 5 stars		Reiterated Rating	Outperform	$60.00	+32.16%
8/26/2024	Wolfe Research 3 of 5 stars	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$65.00	+36.04%
8/14/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$34.00 ➝ $45.00	+4.65%
8/12/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $38.00	-10.69%
7/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$52.00 ➝ $52.00	+45.41%
Biden's Executive Order, Dems Digital Money Legislation, First Step To (Ad) Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it. This means you must act NOW before it's too late.
7/9/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$31.00 ➝ $36.00	-8.70%
6/17/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00	+38.18%
3/1/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$41.00 ➝ $54.00	+26.46%
2/27/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$39.00 ➝ $56.00	+27.88%
2/23/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$34.00 ➝ $47.00	+11.96%
2/23/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$35.00 ➝ $55.00	+35.84%
1/3/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$45.00 ➝ $30.00	+18.34%
8/4/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$36.00 ➝ $37.00	+55.92%
5/4/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform
12/16/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$40.00 ➝ $52.00	+95.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:07 PM ET.

KYMR Forecast - Frequently Asked Questions

What is Kymera Therapeutics' forecast for 2024?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Kymera Therapeutics is $48.67, with a high forecast of $65.00 and a low forecast of $30.00.
Should I buy or sell Kymera Therapeutics stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KYMR shares.
Does Kymera Therapeutics's stock price have much upside?: According to analysts, Kymera Therapeutics's stock has a predicted upside of 21.28% based on their 12-month stock forecasts.
Has Kymera Therapeutics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Kymera Therapeutics's stock had 2 upgrades by analysts.
What analysts cover Kymera Therapeutics?: Kymera Therapeutics has been rated by research analysts at B. Riley, Leerink Partners, Leerink Partnrs, Morgan Stanley, Oppenheimer, Wells Fargo & Company, and Wolfe Research in the past 90 days.
Do Wall Street analysts like Kymera Therapeutics more than its competitors?: Analysts like Kymera Therapeutics less than other "medical" companies. The consensus rating score for Kymera Therapeutics is 2.77 while the average consensus rating score for "medical" companies is 2.77. Learn more on how KYMR compares to other companies.